chronic lymphocytic leukaemia

News

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calqu...

AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in chronic lymphocytic leukaemia (CLL) that it says show a safety advantage over Imb

News

Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.

TG Therapeutics completes FDA filing for Roche challenger in...

TG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab with the oral drug Ukoniq (umbralisib) as a treatment for chronic

News

NICE backs AZ’s Calquence for new use in leukaemia

AstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS England patients with chronic lymphocytic leukaemia (CLL) who can’t be treated

News

AZ says Calquence is a safer drug than Imbruvica

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

TG Therapeutics raises funds for cancer combination drug

TG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month after lifting the lid on phase 3 data from its potential challenger

News

CLL patients in England to get AZ's Calquence after okay fro...

NHS England is to grant immediate access to AstraZeneca’s cancer drug Calquence (acalabrutinib) for certain patients with chronic lymphocytic leukaemia (CLL) after NICE backed it in first d

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calqu...

TG Therapeutics completes FDA filing for Roche challenger in...

NICE backs AZ’s Calquence for new use in leukaemia

AZ says Calquence is a safer drug than Imbruvica

TG Therapeutics raises funds for cancer combination drug

CLL patients in England to get AZ's Calquence after okay fro...

Ex-BioNTech execs launch 'AI-native' cancer company

Discover a new era of healthcare panel engagement: Grounded ...

chronic lymphocytic leukaemia

Editor's Picks